NICE's response to comments on the draft scope and provisional stakeholder list (PDF 352 KB) Published: 17 March 2025
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
Please note that following on from a request received from the company, this appraisal has been scheduled back into the work programme. The appraisal is now anticipated to begin in mid-March 2025 when we will write to you about how you can get involved.
For operational reasons, the first committee meeting discussion of this appraisal has been rescheduled for Wednesday 10 December 2025.
The company, AbbVie, has asked to submit more evidence as part of the draft guidance response and requires more time to do this. Therefore, the committee meeting discussion on 4 March 2026 will be rearranged to a later date. The website will be updated with the new committee meeting date once it is known.